MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

被引：0
|
作者：
Ou, S. H. [1 ]
Garcia, V. Moreno [2 ]
Bazo, I. Gil [3 ]
Prenen, H. [4 ]
Moreno, I. [5 ]
Johnson, M. [6 ]
Alvarez, E. Castanon [7 ]
Nagasaka, M. [1 ]
Adeyemi, S. [8 ]
Barasa, B. [9 ]
Bol, K. [10 ]
Doze, P. [10 ]
Engbers, A. [10 ]
Joe, A. K. [10 ]
Stalbovskaya, V. [8 ]
Laus, G. [10 ]
Call, J. [11 ]
机构：
[1] Univ Calif Irvine, Dept Med Div Hematol Oncol, Sch Med, Irvine, CA USA
[2] Start Madrid FJD, Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[3] Univ Navarra Clin, Dept Med Oncol, Pamplona, Spain
[4] Univ Antwerp Hosp, Oncol, Antwerp, Belgium
[5] HM Sanchinarro Univ Hosp, Start Madrid, CIOCC, Madrid, Spain
[6] Sarah Cannon Res Inst LLC, Lung Canc Res, Nashville, TN USA
[7] Univ Navarra Clin, Dept Med Oncol, Madrid, Spain
[8] Merus, Biometr, Utrecht, Netherlands
[9] Merus, Translat Res, Utrecht, Netherlands
[10] Merus, Clin, Utrecht, Netherlands
[11] START Mt Reg, Med Oncol, Salt Lake City, UT USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
341
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
    Bossi, P.
    Minuti, G.
    Brana, I.
    Garcia, V. Moreno
    Boni, V.
    Jamme, P.
    Call, J. A.
    Yan, C.
    Barasa, B.
    Doze, P.
    Joe, A. K.
    Laus, G.
    Daste, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1610 - S1611
  • [2] Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)
    Wang, Jie
    Zhong, Jia
    Wu, Lin
    Chen, Bolin
    Wang, Zhe-Hai
    Yao, Yu
    Dong, Xiaorong
    Li, Wei
    Ren, Xiubao
    Hou, Xiaoming
    Zang, Ai-min
    Qu, Xiujuan
    Zhang, Guojun
    Wang, Yongsheng
    Bai, Yuansong
    Liu, Linlin
    Yu, Guohua
    Chen, Xingwu
    Ding, Lieming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab
    de Gorter, David J. J.
    Deshiere, Alexandre
    Kramer, Arjen
    van Rosmalen, Martijn
    Mortensen, Franziska
    Geuijen, Cecile
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
    Brandao, Mariana da Rocha Almeida
    Zugazagoitia, Jon
    Dingemans, Anne-Marie C.
    Duruisseaux, Michael
    Parent, Pauline
    Juan-Vidal, Oscar
    Spira, Alexander I.
    Vicier, Cecile
    Zalcman, Gerard
    Barasa, Ben
    Yan, Chris
    Doze, Petra
    Joe, Andrew K.
    Laus, Gianluca
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A PHASE 1 STUDY OF NECITUMUMAB (ANTI-EGFR MONOCLONAL ANTIBODY) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Yosuke
    Tanabe, Yuko
    Honda, Kazunori
    Asahina, Hajime
    Enatu, Sotaro
    Kurek, Raffael
    Yamada, Yasuhide
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
  • [6] Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
    Cappuzzo, F.
    Moreno Garcia, V.
    Ou, S-H. I.
    Brandao, M.
    Sanmamed, M. F.
    Helissey, C.
    Wislez, M.
    Call, J. A.
    Grisanti, S.
    Johnson, M. L.
    Boni, V.
    Jamme, P.
    Monnet, I.
    Siena, S.
    Yan, C.
    Barasa, B.
    Richard, B.
    Joe, A. K.
    Laus, G.
    Felip, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1671 - S1671
  • [7] Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas
    Voon, P. J.
    Tan, J. -L.
    Spira, A. I.
    Keam, B.
    Lee, S. -H.
    Xia, B.
    Artis, E.
    Dobbs, J.
    Baudelet, C.
    Baig, M.
    Bauml, J. M.
    Sendur, M. A.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S657 - S658
  • [8] A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
    Cleary, James M.
    Yee, Lorrin Kwock-Chong
    Azad, Nilofer
    Carducci, Michael
    Cosgrove, David
    Limaye, Sewanti
    Gandhi, Leena
    Pedersen, Michelle
    Ansell, Peter
    Ames, William
    Sharma, Shringi
    Hsu, Ya-Hui
    Munasinghe, Wijith
    Reilly, Edward
    Holen, Kyle D.
    Humerickhouse, Rod
    CANCER RESEARCH, 2012, 72
  • [9] The bispecific antibody MCLA-129 impairs NSCLC tumor growth by targeting EGFR and c-MET, inhibiting ligand-induced signaling and promoting ADCC and ADCP.
    de Gorter, David J.
    Deshiere, Alexandre
    van Rosmalen, Martijn
    Wohn, Christian
    Eppink, Berina
    Gallenne, Tristan
    Klooster, Rinse
    Mao, Li
    Xu, Wenxin
    Deng, Liang
    Shu, Qingyu
    Liu, Wei
    de Kruif, John
    Di Matteo, Mario
    Mazzone, Massimiliano
    Throsby, Mark
    Geuijen, Cecile A.
    CANCER RESEARCH, 2021, 81 (13)
  • [10] Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
    Strickler, John H.
    LoRusso, Patricia
    Salgia, Ravi
    Kang, Yoon-Koo
    Yen, Chia Jui
    Lin, Chia-Chi
    Ansell, Peter
    Motwani, Monica
    Wong, Shekman
    Yue, Huibin
    Wang, Lan
    Reilly, Edward
    Afar, Daniel
    Naumovski, Louie
    Ramanathan, Ramesh K.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1210 - 1217
12345